Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Leveragen Inc. is currently navigating the patent prosecution process within the Biotechnology & Pharmaceuticals technology area. The portfolio shows 1 pending office action, which is being reviewed by 1 distinct examiner. This singular focus indicates that the company's immediate patent hurdles are concentrated rather than spread across multiple technologies. The 1 distinct art unit involved further emphasizes the specialized nature of the current pending application.
WEHBE, ANNE MARIE SABRINA is identified as the busiest examiner for Leveragen Inc., with 1 pending office action under her jurisdiction. Since there is only 1 pending office action in total for the company, this examiner is responsible for the entirety of the portfolio's active challenges. The presence of 1 distinct examiner and 1 distinct art unit suggests that the prosecution path is streamlined. Practitioners should analyze the specific examiner's past decisions within the Biotechnology & Pharmaceuticals field to better predict the outcome for this 1 pending action.
The alignment of the busiest examiner's workload with the total pending actions simplifies the management of the portfolio's current legal standing. This focused environment, involving 1 distinct examiner and 1 distinct art unit, provides a clear path for the company's intellectual property goals. Understanding the tendencies of WEHBE, ANNE MARIE SABRINA will be important for the prosecution process.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting + other | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| WEHBE, ANNE MARIE SABRINA | 1 | 57.3% | +43.3% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18289508 | ENGINEERED NON-HUMAN ANIMALS FOR PRODUCING ANTIBODIES | WEHBE, ANNE MARIE SABRINA | — |
| Art Unit | Apps |
|---|---|
| 1634 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18289508 | ENGINEERED NON-HUMAN ANIMALS FOR PRODUCING ANTIBODIES | WEHBE, ANNE MARIE SABRINA | 1634 | §102§103§112DP | Non-Final OA | — | Pending | Nov 03, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialLeveragen Inc. has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Anne Marie Sabrina Wehbe has the most, with 1 of Leveragen Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
